Skip to main content

Drug Therapy in Brugada Syndrome

Buy Article:

$55.00 plus tax (Refund Policy)

Sudden cardiac death in healthy individuals with structurally normal hearts and a characteristic morphology of the QRS complex resembling a right bundle branch block with elevation of the ST segment in V1 to V3 is known as Brugada syndrome (BrS). Although placement of an implantable cardioverter-defibrillator is considered the only effective therapy for symptomatic patients, some authors have repeatedly reported a beneficial effect of quinidine and isoproterenol in patients with BrS. Also, isolated case reports on the usefulness of cilostazol, sotalol, and mexiletine have been described. The present article reviews the mechanisms by which these drugs may act and their role in the pharmacotherapy of BrS. Other possible agents, mainly Ito blockers, are also reviewed.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: arrhythmic storm; brugada syndrome; cilostazol; isoproterenol; mexiletine; quinidine; sotalol; sudden cardiac death; tedisamil; ventricular fibrillation

Document Type: Review Article

Affiliations: Instituto Nacional de Cardiologia "Ignacio Chavez", Departamento de Electrocardiologia Juan Badiano 1, Seccion XVI, Tlalpan 14080, Mexico, D.F. Mexico.

Publication date: 2005-10-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more